Is the diet pill market too profitable to lose?

Why do you think $Pfizer(PFE.US)$ decided to progress with Danuglipron? (Can't give up this huge market?

The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US)$ Orforglipron and $Structure Therapeutics(GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA